Molecule intelOpportunity: ModerateEssential

Etoposide

20 brands · 17 companies · product forms

ATC: L01CB01

Opportunity snapshot

Launch attractiveness
46
Market saturation
44
Price room
100
Regulatory risk
0
20
brands
17
companies
Rs 1,135.92
median price
12
price points
40.66x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 15%

Price room

Across observed sources and strengths
CheapestRs 777.18
MedianRs 1,135.92
Most expensiveRs 31,598.91
Spread40.66×
Sources: DRAP-official

max/min price ratio 40.66x across 12 trusted points (Rs 777.18-31598.91). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 10 live products for Etoposide — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(56) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

17 canonical companies and 20 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 40.66x across 12 trusted points (Rs 777.18-31598.91). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.